172 related articles for article (PubMed ID: 35059910)
21. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF
BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689
[TBL] [Abstract][Full Text] [Related]
22. [COX-2 inhibitor celecoxib can suppress the proliferation of FLT3-ITD positive acute myeloid leukemia cells with prominent down regulation of MEK/MCL-1 expression in vitro].
Du LX; Jia YQ; Meng WT; Shi FF; Zhong XS; Ma LL; Yuan J; Zeng JS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1157-61. PubMed ID: 24156425
[TBL] [Abstract][Full Text] [Related]
23. Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia.
Wobus M; Bornhäuser M; Jacobi A; Kräter M; Otto O; Ortlepp C; Guck J; Ehninger G; Thiede C; Oelschlägel U
Oncotarget; 2015 Nov; 6(36):38804-15. PubMed ID: 26462154
[TBL] [Abstract][Full Text] [Related]
24. Vaticanol C, a phytoalexin, induces apoptosis of leukemia and cancer cells by modulating expression of multiple sphingolipid metabolic enzymes.
Inoue C; Sobue S; Mizutani N; Kawamoto Y; Nishizawa Y; Ichihara M; Takeuchi T; Hayakawa F; Suzuki M; Ito T; Nozawa Y; Murate T
Nagoya J Med Sci; 2020 May; 82(2):261-280. PubMed ID: 32581406
[TBL] [Abstract][Full Text] [Related]
25. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.
Naganna N; Opoku-Temeng C; Choi EY; Larocque E; Chang ET; Carter-Cooper BA; Wang M; Torregrosa-Allen SE; Elzey BD; Lapidus RG; Sintim HO
EBioMedicine; 2019 Feb; 40():231-239. PubMed ID: 30686755
[TBL] [Abstract][Full Text] [Related]
26. Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.
Roolf C; Dybowski N; Sekora A; Mueller S; Knuebel G; Tebbe A; Murua Escobar H; Godl K; Junghanss C; Schaab C
Mol Cell Proteomics; 2017 Jul; 16(7):1365-1376. PubMed ID: 28450419
[TBL] [Abstract][Full Text] [Related]
27. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
Yoshimoto G; Miyamoto T; Jabbarzadeh-Tabrizi S; Iino T; Rocnik JL; Kikushige Y; Mori Y; Shima T; Iwasaki H; Takenaka K; Nagafuji K; Mizuno S; Niiro H; Gilliland GD; Akashi K
Blood; 2009 Dec; 114(24):5034-43. PubMed ID: 19808698
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Oxazol-2-amine Derivatives as Potent Novel FLT3 Inhibitors.
Kim HJ; Ryu H; Song JY; Hwang SG; Jalde SS; Choi HK; Ahn J
Molecules; 2020 Nov; 25(21):. PubMed ID: 33167505
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM
Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885
[TBL] [Abstract][Full Text] [Related]
30. Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia.
Yuan LL; Green A; David L; Dozier C; Récher C; Didier C; Tamburini J; Manenti S
Leuk Res; 2014 Nov; 38(11):1342-9. PubMed ID: 25281057
[TBL] [Abstract][Full Text] [Related]
31. Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML.
Dany M; Gencer S; Nganga R; Thomas RJ; Oleinik N; Baron KD; Szulc ZM; Ruvolo P; Kornblau S; Andreeff M; Ogretmen B
Blood; 2016 Oct; 128(15):1944-1958. PubMed ID: 27540013
[TBL] [Abstract][Full Text] [Related]
32. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
33. Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.
Skwarska A; Augustin E; Beffinger M; Wojtczyk A; Konicz S; Laskowska K; Polewska J
Biochem Pharmacol; 2015 Jun; 95(4):238-52. PubMed ID: 25896848
[TBL] [Abstract][Full Text] [Related]
34. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
Li X; Yan X; Guo W; Huang X; Huang J; Yu M; Ma Z; Xu Y; Huang S; Li C; Zhou Y; Jin J
Biomed Pharmacother; 2017 Jun; 90():699-704. PubMed ID: 28419965
[TBL] [Abstract][Full Text] [Related]
35. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
[TBL] [Abstract][Full Text] [Related]
36. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
Pietschmann K; Bolck HA; Buchwald M; Spielberg S; Polzer H; Spiekermann K; Bug G; Heinzel T; Böhmer FD; Krämer OH
Mol Cancer Ther; 2012 Nov; 11(11):2373-83. PubMed ID: 22942377
[TBL] [Abstract][Full Text] [Related]
37. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S
Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205
[TBL] [Abstract][Full Text] [Related]
38. Anti-leukemic Activity of AIU2008 in FLT3-ITD-positive Acute Myeloid Leukemia.
Kim HJ; Ryu H; Choi HK; Song JY; Hwang SG; Ahn J
Anticancer Res; 2021 Feb; 41(2):731-737. PubMed ID: 33517277
[TBL] [Abstract][Full Text] [Related]
39. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
[TBL] [Abstract][Full Text] [Related]
40. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]